BRAF Mutation Analysis
Coverage and medical necessity criteria for BRAF mutation testing in tumor tissue to identify patients who would benefit from FDA-approved BRAF inhibitors; applies to EmblemHealth members and treating providers seeking prior authorization.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medically Necessary Indications
Covered when ALL of the following are met
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.